FDA Letter: Risk Evaluation and Mitigation Strategies of Certain Opioids

Drugs

Joint Letter to FDA strongly supporting initiatives that achieve balance between the risks and benefits in the utilization of certain opioids.

Multiple Organizations (16)

Food and Drug Administration, FDA, Risk Evaluation and Mitigation Strategies, REMS, Drug Enforcement Agency, DEA, continuing medical education, CME, prescription monitoring programs, PMP, conditions for safe use, opioid

Tue, 06/30/2009 - 4:10 PM EDT

Thu, 09/26/2019 - 2:06 PM EDT

8

fda_opioid_utilization_2009.pdf

{"Author":"Multiple Organizations (16)","Company":"AMA","CreationDate":"2009-06-30T16:10:28-04:00","Creator":"Acrobat PDFMaker 6.0 for Word","Keywords":"\"Food and Drug Administration, FDA, Risk Evaluation and Mitigation Strategies, REMS, Drug Enforcement Agency, DEA, continuing medical education, CME, prescription monitoring programs, PMP, conditions for safe use, opioid\"","ModDate":"2019-09-26T14:06:16-04:00","Producer":"Acrobat Distiller 6.0 (Windows)","SourceModified":"2009-06-30T20:10:21+00:00","Subject":"Drugs","Title":" FDA Letter: Risk Evaluation and Mitigation Strategies of Certain Opioids","Type#2FCategory":"Correspondance","Pages":8,"pdf:producer":"Acrobat Distiller 6.0 (Windows)","pdf:keywords":"\"Food and Drug Administration, FDA, Risk Evaluation and Mitigation Strategies, REMS, Drug Enforcement Agency, DEA, continuing medical education, CME, prescription monitoring programs, PMP, conditions for safe use, opioid\"","xmp:creatortool":"Acrobat PDFMaker 6.0 for Word","xmp:createdate":"2009-06-30T16:10:28-04:00","xmp:modifydate":"2019-09-26T14:06:16-04:00","xmp:metadatadate":"2019-09-26T14:06:16-04:00","dc:format":"application\/pdf","dc:title":" FDA Letter: Risk Evaluation and Mitigation Strategies of Certain Opioids","dc:creator":"Multiple Organizations (16)","dc:description":"Drugs","dc:subject":"Food and Drug Administration, FDA, Risk Evaluation and Mitigation Strategies, REMS, Drug Enforcement Agency, DEA, continuing medical education, CME, prescription monitoring programs, PMP, conditions for safe use, opioid","pdfx:company":"AMA","pdfx:sourcemodified":"D:20090630201021","pdfx:type\u2182002fcategory":"Correspondance","xmpmm:documentid":"uuid:9afd403b-55bf-472d-86c3-77989a388a5a","xmpmm:instanceid":"uuid:825698c0-7af0-46b1-9e74-4b167a6b3567"}

2009